CHRM4 and 5 receptors were altered in breast (BRCA-LumA, BRCA-LumB, and BRCA-Basal), stomach, lung (LUAD and LUSC), colon, liver, and prostate cancers; CHRM3 receptor was altered in breast (BRCA-LumA and BRCA-Basal), stomach, lung (LUAD and LUSC), liver, and prostate cancer; CHRM2 was altered in breast (BRCA-LumA and BRCA-LumB), stomach, colon, liver, and prostate cancer; and CHRM1 receptor was altered in breast (BRCA-LumA), stomach, and prostate cancer (Scheme 1). Here, CHRM4 is linked to prostate cancer.